Full TitleA Phase I/II Study of Bendamustine and Melphalan (+/- Rituximab) conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
The standard treatment for recurrent or persistent B-cell lymphoma involves high doses of chemotherapy followed by “rescuing” the bone marrow with reinfusion of a patient’s own stem cells. However, these high doses of chemotherapy often have side effects in elderly patients. Doctors are seeking effective therapies for elderly patients using lower doses of chemotherapy or immunotherapy.
In this study, researchers are evaluating the safety and effectiveness of a different chemo-immunotherapy in elderly patients with recurrent or persistent B-cell lymphoma. The therapy is a combination the drugs rituximab, bendamustine, and melphalan, followed by reinfusion of one’s own stem cells (autologous stem cell transplantation). This treatment is expected to have fewer side effects. All of the medications are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have recurrent or persistent B-cell lymphoma.
- Patients may not have previously had stem cell transplantation.
- This study is for patients age 70 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Parastoo Dahi at 212-639-5846.